



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Robert A. Ashley	Examiner:	Unassigned
Serial No.:	10/757,656	Group Art Unit:	Unassigned
Confirmation No:	Unassigned	Docket:	512-53 DIV
Filed:	January 14, 2004	Dated:	March 8, 2004
For:	METHODS OF TREATING ACNE		

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on March 8, 2004

Signature: Carlo H. Bryan

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.

§1.56, Applicant submits herewith the following Supplemental Information Disclosure

Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

REFERENCES

1. Bikowski, J.B., "Treatment of rosacea with doxycycline monohydrate," Curtis.
2000 Aug., 66(2):149-152.


2. Jimenez-Acosta, "Response to tetracycline of telangiectasias in male hemophiliac with human immunodeficiency virus infection," J. Am. Acad. Dermatol. 1988 Aug., 19(2 Pt. 1):369-379.
3. Torresani, C., "Clarithromycin versus doxycycline in the treatment of rosacea," Int. J. Clin. Dermatol. 1997 Dec., 36(12):942-946.
4. McClellan, K.J., "Topical Metronidazole. A review of its use in rosacea," Am. J. Clin. Dermatol. 2000 May-June, 1(3):191-199.
5. Quarterman, M.J., "Ocular Rosacea. Signs, symptoms and tear studies before and after treatment with doxycycline," Arch. Dermatol. 1997 Jan., 133(1):49-54.

A separate listing of the references has been set forth on the enclosed form PTO-1449. The Examiner is respectfully requested to consider the references in their entirety, and to indicate that he or she has done so by initialing the enclosed Patent and Trademark Office Form 1449.

Applicant is not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicant's attorney at the telephone number set forth below.

Applicant does not believe that any fees are due. However, if any fees are due, please deduct such sum from Deposit Account No. 08-2461.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Susan A. Sipos', is written over a horizontal line.

Susan A. Sipos
Registration No.: 43,128
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550

SAS/cb

185959_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
512-53 DIV

SERIAL NO.
10/757,656

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Ashley, Robert A.

CONFIRMATION NO.
Unassigned

(Use several sheets if necessary)

FILING DATE
January 14, 2004

GROUP
Unassigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Bikowski, J.B., "Treatment of rosacea with doxycycline monohydrate," Curtis. 2000 Aug., 66(2):149-152.
			Jimenez-Acosta, "Response to tetracycline of telangiectasias in male hemophiliac with human immunodeficiency virus infection," J. Am. Acad. Dermatol. 1988 Aug., 19(2 Pt. 1):369-379.
			Torresani, C., "Clarithromycin versus doxycycline in the treatment of rosacea," Int. J. Clin. Dermatol. 1997 Dec., 36(12):942-946.
			McClellan, K.J., "Topical Metronidazole. A review of its use in rosacea," Am. J. Clin. Dermatol. 2000 May-June, 1(3):191-199.
			Quarterman, M.J., "Ocular Rosacea. Signs, symptoms and tear studies before and after treatment with doxycycline," Arch. Dermatol. 1997 Jan., 133(1):49-54.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.